Stamaril

BIOLOGICAL7 trials

Sponsors

Sanofi Pasteur, GlaxoSmithKline, Serum Institute of India Pvt. Ltd., Singapore General Hospital, GlaxoSmithKline Biologicals

Conditions

Infectious DiseaseJapanese EncephalitisMalariaMalaria PaediatricsMalaria VaccinesViral InfectionYellow FeverYellow fever

Phase 2

An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity

Singapore General HospitalInfectious Disease, Japanese Encephalitis, Viral Infection +1

Start: 2022-09-28End: 2025-10-31Target: 70Updated: 2023-04-12

Controlled Study of Immunogenicity and Safety of the Investigational vYF Candidate Vaccine in Comparison to Stamaril® in Adults

Active, not recruitingCTIS2022-502047-35-00

Sanofi PasteurYellow fever

Start: 2021-10-07Target: 570Updated: 2026-01-12

Phase 3

Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine.

CompletedNCT02699099

GlaxoSmithKlineMalaria, Malaria Vaccines

Start: 2017-05-10End: 2020-10-07Updated: 2021-09-29

Study on Yellow Fever Vaccine developed by Serum Institute of India Pvt. Ltd. for comparison of safety and immunogenicity with other vaccine (STAMARIL) In Healthy Infants

RecruitingPACTR202206910703861

Serum Institute of India Pvt Ltd.Yellow Fever

Start: 2022-07-15Target: 2216Updated: 2026-01-27

Study to Compare Safety and Immunogenicity of Yellow Fever Vaccine of Serum Institute of India with with STAMARIL

RecruitingPACTR202206719871582

Serum Institute of India Pvt Ltd.Yellow Fever

Start: 2022-07-30Target: 1824Updated: 2026-01-27

A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL

CompletedNCT05421611

Serum Institute of India Pvt. Ltd.Yellow Fever

Start: 2023-05-11End: 2024-05-10Updated: 2025-05-07

Unknown Phase

Immunogenicity & safety of GSK Biologicals malaria vaccine given at 6,7.5 &9 months of age coadministered with measles,rubella & yellow fever vaccines

Active, not recruitingPACTR201602001483150

GlaxoSmithKline BiologicalsMalaria Paediatrics

Start: 2016-09-14Target: 700Updated: 2026-01-27

Related Papers

Vaccine-induced T cell responses control Orthoflavivirus challenge infection without neutralizing antibodies in humans.

2025-01-1022 citations

An experimental medicine decipher of a minimum correlate of cellular immunity: Study protocol for a double-blind randomized controlled trial

Frontiers in Immunology2023-03-104 citations

Immunogenicity and safety of the RTS,S/AS01 malaria vaccine co-administered with measles, rubella and yellow fever vaccines in Ghanaian children: A phase IIIb, multi-center, non-inferiority, randomized, open, controlled trial.

2020-03-1710 citations